Back to Search
Start Over
A high-purity double virus inactivated FVIII/vWF concentrate (Immunate) in the successful treatment of patients with von Willebrand disease
- Source :
- Haemophilia. 8:836-836
- Publication Year :
- 2002
- Publisher :
- Wiley, 2002.
-
Abstract
- Patients with severe forms of von Willebrand disease (vWD) most frequently require substitution of both factor VIII and von Willebrand factor (vWF). Immunate is a high-purity, double-virus inactivated FVIII/vWF concentrate derived from human plasma. The clinical efficacy of Immunate concerning the management of acute bleeding episodes and surgical prophylaxis in patients with von Willebrand disease (vWD) is being investigated and documented in a prospective, phase III, open-label, single-armed multicenter trial. Data on its pharmacokinetics are collected, and the product's safety with respect to adverse experiences is monitored.
- Subjects :
- congenital, hereditary, and neonatal diseases and abnormalities
biology
business.industry
Hematology
General Medicine
medicine.disease
Virus
Surgical prophylaxis
Von Willebrand factor
Pharmacokinetics
hemic and lymphatic diseases
Multicenter trial
Immunology
biology.protein
Von Willebrand disease
medicine
In patient
Clinical efficacy
business
Genetics (clinical)
circulatory and respiratory physiology
Subjects
Details
- ISSN :
- 13518216
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Haemophilia
- Accession number :
- edsair.doi...........a3d80ba19be3ac5448d3130966be6242